康美德 CNMD

Mr. Beyer was promoted to the role of President and Chief Executive Officer and appointed to the Board of Directors in January 2025. Prior to this, Mr. Beyer was the Company's Chief Operating Officer from April 2024 to December 2024, the President International and Global Orthopedics from October 2020 to April 2024, and President of CONMED International from December 2014 to October 2020. Prior to joining the Company, Mr. Beyer served as Chief Executive Officer of ICNet, a privately held infectious control software company, from 2010 until the company was sold in 2014. Prior to this, Mr. Beyer spent 21 years at Stryker Corporation (NYSE: SYK) where he led Stryker Europe from 2005 to 2009, Stryker UK, South Africa and Ireland from 2002 to 2005, and Stryker Medical from 1999 to 2002. Mr. Beyer is on the Board of Bioventus (NASDAQ: BVS), previously Misonix, where he is a member of the Audit Committee. Mr. Beyer graduated from Kalamazoo College with a Bachelor of Arts in Economics and Western Michigan University with a Master of Business Administration in Finance. He also completed Harvard Business School's Advanced Management Program.

Ms. Foust joined the Company in November 2024 as Executive Vice President, General Counsel and Corporate Secretary. Prior to joining the Company, Ms. Foust held the role of Senior Vice President, Deputy General Counsel at Cardinal Health (NYSE: CAH) since 2021. Prior to this role, Ms. Foust held several roles across legal and compliance with increasing responsibility at Cardinal Health since 2009. Before Cardinal Health, Ms. Foust held various legal roles supporting the U.S. and International nutrition business of Abbott Laboratories (NYSE: ABT). Ms. Foust started her career in private practice at Bailey Cavalieri, LLC, where she focused on banking and financing transactions. She received her undergraduate degree and law degree from The Ohio State University.

Mr. Lalomia was promoted to the role of Executive Vice President, Regulatory Affairs, Quality Assurance, Clinical Affairs, and Commercial Operations in March 2025. He serves as EVP, Regulatory Affairs, Quality Assurance, Clinical Affairs, Commercial Operations, and IT. Prior to this, he assumed the role of Vice President, Quality Assurance, Regulatory Affairs, Customer Experience, and Logistics in May 2023. Prior to this, Mr. Lalomia joined CONMED as the Vice President, Quality Assurance and Regulatory Affairs in 2019. Prior to joining the Company, Mr. Lalomia worked for Stryker Corporation (NYSE: SYK) from 1996 to 2019, most recently as the Vice President, Quality Assurance and Facilities Management of the Stryker Instruments Division from 2014 to 2019. Mr. Lalomia holds a Master of Business Administration from the University of Notre Dame and a Bachelor of Science in Mechanical Engineering from Western Michigan University.

Mr. Shagory joined the Company as Executive Vice President, Strategy and Corporate Development in May 2015. Mr. Shagory has more than 25 years of experience in healthcare venture investing and mergers and acquisitions through his previous venture capital, investment banking, and corporate roles. Prior to joining the Company, Mr. Shagory led the strategy and business development efforts for Cardinal Health's (NYSE: CAH) Medical Products Group within the Medical Segment from 2013 to 2015, where he played a key role in Cardinal Health's entry into interventional cardiovascular and the advanced wound care categories. Prior to that, Mr. Shagory led the healthcare and life sciences investment effort at Baird Venture Partners from 2004 to 2013, focusing on medical technology and research tools and diagnostics. Mr. Shagory earned a Master of Business Administration from Dartmouth's Tuck School of Business and a Bachelor of Science in Finance from Miami University in Oxford, Ohio.

Mr. Kaye has served as the Executive Vice President and Chief Financial Officer of Elevance Health (Elevance) since 2023. Prior to joining Elevance, he served as the Executive Vice President and Chief Financial Officer of Moody's Corporation (Moody's) from 2021 to 2023, with responsibility for all global finance activities across the company and as Senior Vice President-Chief Financial Officer from 2018 to 2021. Prior to Moody's, he served as Senior Vice President and Head of Financial Planning and Analysis at Massachusetts Mutual Life Insurance Company (MassMutual) from 2016 until 2018, and Chief Financial Officer of MassMutual U.S. since 2015. Prior to MassMutual, Mr. Kaye served as Chief Financial Officer and Senior Vice President, Retirement Solutions, at Voya Financial (formerly ING U.S.) from 2011 to 2015, and Mr. Kaye previously held various senior financial and risk reporting positions at ING U.S. and ING Group. Prior to that, Mr. Kaye worked in the investment banking division of Credit Suisse First Boston. Mr. Kaye has served as a Director on the Board of BCS Financial Corporation since 2024. Mr. Kaye holds a bachelor's degree in Actuarial Science and Statistics from the University of Pennsylvania and a Masters of Business Administration in Finance from The Wharton School at the University of Pennsylvania. On February 24, 2025, the Board of Directors of CONMED Corporation increased the size of the Board to nine directors and appointed Mark Kaye as a director effective immediately.

Ms. Schwarzentraub held various roles at Caterpillar, Inc. (NYSE: CAT) from 1990 to 2020. Most recently, she was the Director and Divisional Chief Financial Officer for their Global Information Services Division from 2017 to 2020. Prior to this, she held roles including Director of Caterpillar's Global Component Manufacturing and Supply Chain, Vice President of Caterpillar Logistics Services Inc., Director of Caterpillar's Parts Distribution, and Director of Global Finance Transformation. Prior to these roles, Ms. Schwarzentraub held several positions of increasing responsibility within Caterpillar. Ms. Schwarzentraub received her Master of Business Administration and Bachelor of Science in Accounting from Bradley University.

Mr. Bronson served as Executive Vice President and Chief Financial Officer of PSS World Medical, Inc. from 2002 until it was acquired by McKesson Corp in 2013. Prior to that, he was Chief Financial Officer of Digineer, Inc. from 2001 to 2002 and of VWR Scientific Products from 1995 to 1999, when it was acquired by Merck KGaA. Mr. Bronson previously spent 15 years at Baxter Healthcare, Inc., where he held various senior financial executive positions. He was a director and a member of the Audit Committee of Labsco, Inc. until 2016 and was a director and Audit Committee Chair of AxelaCare, Inc. through November 2015. Mr. Bronson received his Master of Science in Management Studies from Northwestern University's Kellogg School of Business and his Bachelor of Science in Accounting from California State University, Fullerton.

Mr. Farkas has spent more than 40 years at Bain & Company. Mr. Farkas became an Advisory Partner of Bain & Company in July 2015. Prior to this, Mr. Farkas was a Senior Partner at Bain & Company, served as the Global Co-Head of Bain's Healthcare Practice, and advised leading medical technology and pharmaceutical companies in the United States, Europe, and Asia. He also advised academic medical centers and provider organizations in the United States. Mr. Farkas also advised chief executives and senior managers in a wide variety of industries on issues critical to long-term success, including strategy, mergers and acquisitions, and operational effectiveness. He has served as the Managing Director of Bain Canada and as the global leader of Bain & Company's financial services practice. Prior to working at Bain, Mr. Farkas received a Bachelor of Arts from Princeton University and a Master of Business Administration from Harvard Business School. Mr. Farkas is currently on the Boards of the John A. Hartford Foundation, Medzown, Inc., Wellist, LLC, and United Bridge Partners. He also serves as Chair of the Board of Medicinal Genomics Corporation. Previously, Mr. Farkas served on the Harvard Medical School Board from 2005 to 2017.

On September 8, 2025, the Board of Directors (the Board) of CONMED Corporation (the Company) appointed Kim Kelderman as a director effective immediately. Mr. Kelderman was appointed to the Corporate Governance and Nominating Committee and the Strategy Committee. The Board determined that Mr. Kelderman is independent and meets the applicable director independence requirements of the New York Stock Exchange and the Company's director independence standards, as adopted by the Board. Mr. Kelderman has been President, Chief Executive Officer, and member of the Board of Bio-Techne (NASDAQ: TECH) since February 2024, having joined Bio-Techne in April 2018, as President, Diagnostics and Genomics, and having served as Chief Operating Officer from November 2023 to January 2024. Prior to Bio-Techne, Mr. Kelderman was employed at Thermo Fisher Scientific where he led three different businesses of increasing scale and complexity. Mr. Kelderman managed the Platforms and Content of the Genetic Sciences Division, where he was responsible for the Instrumentation, Software, Consumables and Assays businesses, and brands such as Applied Biosystems and legacy Affymetrix. Before joining Thermo Fisher, Mr. Kelderman served as Senior Segment Leader at Becton Dickinson, managing the global Blood Tubes Vacutainer business. Mr. Kelderman holds a Bachelor of Science degree from Hogeschool Heerlen of Applied Sciences in the Netherlands. His experience on Other Public Company Boards includes Bio-Techne Corporation (Nasdaq: TECH), Since 2024, and boards Analytical, Life Science & Diagnostics Association, Since 2023, StatLab Medical Products, Since 2021.

On May 19, 2026, the Board of Directors appointed Ms. Jeff Mirviss as Director effective on July 1, 2026. Most recently, he served as Executive Vice President and Global President of Peripheral Interventions at Boston Scientific from 2020 to 2025, where he led a multi-billion dollar global business focused on therapies for vascular disease and cancer. In this role, he also had leadership responsibility for the Company's Latin America and Canada regions, as well as its Government Affairs function. Previously, Mr. Mirviss served as Senior Vice President and Global President of Peripheral Interventions from 2013 to 2020, and as Global President of Peripheral Interventions from 2011 to 2013.. Prior to these roles, Mr. Mirviss held positions of increasing responsibility at Boston Scientific, including Group Vice President of Global Marketing for the Company's Cardiology, Rhythm and Vascular businesses. Mr. Mirviss holds a B.I.S. in Marketing from the University of Minnesota and an MBA from the University of St. Thomas.

On January 27, 2025 , Andrew Moller, started serving in the role of Vice President, Corporate Controller of CONMED Corporation. On April 1, 2025, Mr. Moller was appointed Principal Accounting Officer. Mr. Moller served in a variety of roles at Smith & Nephew plc between 2019 and joining the Company, most recently as Vice President, Global Process Owner - Finance and previously as Chief Financial Officer - Asia Pacific Group. Prior thereto, Mr. Moller served in a variety of roles at Stanley Black & Decker from 2011 to 2019, including Director of Internal Audit. Mr. Moller is a certified public accountant and holds a Master of International Business Studies from the University of South Carolina and a Bachelor of Science degree in Business Administration from College of Charleston. On March 13, 2026, CONMED Corporation announced that Andrew Moller, will be appointed Interim Principal Financial Officer of the Company effective March 15, 2026.

Mr. Glaze joined the Company as Chief Information Officer in November 2023. Prior to joining CONMED, he was IT Vice President, North America at Teva Pharmaceuticals (NYSE: TEVA) from August 2020 to November 2023. Prior to working at Teva Pharmaceuticals, Mr. Glaze was the IT Vice President, North America for SUN Pharmaceuticals (NSE: SUNPHARMA) from 2016 to 2020, IT Vice President at Ikaria (now Mallinckrodt Pharmaceuticals, NYSE: MNK) from 2013 to 2016, Sr. IT Director at Hospira (now Pfizer, NYSE: PFE) from 2010 to 2013, and held various positions at Johnson and Johnson (NYSE: JNJ) from 2002 to 2010. Mr. Glaze began his career in consulting, working at Andersen Consulting (now Accenture), Price Waterhouse Coopers, IBM, and KPMG Consulting (now BearingPoint) from 1991 to 2002. Mr. Glaze holds a Master of Business Administration from the Stern School of Business at New York University and a Bachelor of Science from Princeton University.

Mr. Ferrell was promoted to Executive Vice President, Human Resources, in December 2022. Prior to this, Mr. Ferrell served as Vice President, Human Resources, International and Global Orthopedics from 2021 to 2022, and Vice President, Human Resources, International from 2015 to 2021. Prior to joining the Company, Mr. Ferrell worked for Stryker Corporation (NYSE: SYK) from 1994 to 2015, where he was Vice President, Human Resources, for the Orthopedics Group from 2012 to 2015, after previously serving as Vice President, Human Resources and Organizational Development, Europe, from 2009 to 2012. Mr. Ferrell serves on the Board of LECMPA, a non-profit insurer for transportation workers. Mr. Ferrell has a Bachelor of Arts in Psychology from Oakland University, and a Master of Arts in Labor and Industrial Relations from Michigan State University.

Ms. Pelletier was promoted to Treasurer and Vice President, Tax in April 2015. She joined the Company in 2005 in the role of Tax Director. Prior to joining the Company, she worked for PricewaterhouseCoopers, where she most recently served as a Tax Senior Manager. Ms. Pelletier is a Certified Public Accountant and graduated with a Bachelor of Science in Accounting from Le Moyne College. she serves as Treasurer and VP, Tax, Since 2015 , Various tax roles, 2005 - 2015 at CONMED Corporation.

Mr. Matthew Schabacker serves as VP and General Manager, U.S. Advanced Surgical at company. His Professional Experience includes Becton, Dickinson & Company (NYSE: BDX) VP and General Manager, Pharmacy Automation, 2024 - 2025, VP and General Manager, Advanced Drug Delivery Solutions, and Head of Global Business Development for Pharmaceutical Systems, 2022 - 2024, VP, International Infusion, based in Eysins, Switzerland, 2020 - 2022 and Various U.S. and Global sales and marketing leadership roles of increasing responsibility, 2011 - 2020. He serves as Management Consultant at McKinsey & Company, Inc. His Education includes Rutgers University School of Pharmacy, Doctor of Pharmacy, Columbia Business School of Columbia University, Master of Business Administration.